Race Oncology Ltd (ASX:RAC, OTC:RAONF) has struck another blow in the fight against acute myeloid leukemia (AML) with the release of a study investigating the potent anticancer activity of the company’s lead asset, bisantrene.
Showcasing bisantrene’s effectiveness
Conducted by Race Oncology in partnership with the University of Newcastle, Australia, the research showcases bisantrene's effectiveness in both cell-based and mouse models of AML.
The findings were presented at the New Directions in Leukaemia Research conference in Adelaide, held from March 4 to 6, 2024.
The study, entitled 'Preclinical evaluation of bisantrene alone and in combination with decitabine for Acute Myeloid Leukemia', reveals that bisantrene not only excels in eradicating AML cells derived from patients but also significantly enhances anticancer activity when combined with the standard care drug, decitabine.
Low-intensity treatment option
This synergy between bisantrene and decitabine was evident in both laboratory and animal models, highlighting the potential of this combination as a low-intensity treatment option for AML patients.
Further investigation into the cellular mechanisms affected by the bisantrene-decitabine combo has pinpointed key pathways that are targeted, lending additional support to the approach's therapeutic promise.
This preclinical evidence lays the groundwork for upcoming clinical trials involving Race's new bisantrene formulation (RC220) paired with oral decitabine, marking a promising stride towards innovative AML treatments.
The anticipation surrounding this research is high, with plans to submit the data for publication in a high-impact, peer-reviewed journal within the year.
This could herald a new era in the treatment of acute myeloid leukemia, offering hope to patients seeking effective and manageable therapy options.
Investors have welcomed the results with shares as much as 10% higher this morning to A$0.935 while the company's market cap is approximately A$147.72 million.
About Race Oncology
Race Oncology, a leader in cancer care, is advancing its primary compound, bisantrene, noted for its therapeutic efficacy and lower cardiotoxicity compared to traditional treatments.
The company is focused on reformulating bisantrene (RC220) to better serve patients with various cancers.
Race aims to enhance anticancer activity and offer cardioprotection, especially in solid tumours and as a potential treatment for acute myeloid leukaemia.
The company collaborates with top research institutions worldwide and is dedicated to making bisantrene accessible globally, leveraging groundbreaking research to meet the urgent needs of cancer patients.